Across TCGA pan-cancer cohorts, FOXJ3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FOXJ3 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FOXJ3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FOXJ3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where FOXJ3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.829	0.951	.019	5	view →
HNSC	DFS	Median	II,III,IV	0.746	0.564	.029	3	view →
LSCC	OS	Tertile	All	0.945	0.764	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: FOXJ3 tumor-vs-normal RNA expression · all FOXJ3 data types